AML and RC110 are our safety net, but they just reduces the risk of achieving a zero outcome, not eliminate it. The reason why is the success of RAC the company is not only dependent to success in the clinic, but many other factors.
All this talk about failure is getting silly. What has really derisked the company and set it up for massive success is the development of RC220 and the discovery of the cardioprotection + anticancer activity. RAC has the best risk/reward balance it has ever had and things are only getting better.
Ann: Notification of cessation of securities - RAC, page-45
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |